losartan has been researched along with Aortic Diseases in 25 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Aortic Diseases: Pathological processes involving any part of the AORTA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this multicentre, open-label, randomized controlled trial with blinded assessments, we compared losartan treatment with no additional treatment in operated and unoperated adults with Marfan syndrome." | 9.17 | Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. ( de Waard, V; den Hartog, AW; Franken, R; Groenink, M; Marquering, HA; Mulder, BJ; Radonic, T; Scholte, AJ; Spijkerboer, AM; Timmermans, J; van den Berg, MP; Zwinderman, AH, 2013) |
| "To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS)." | 9.17 | Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. ( Chen, CA; Chiu, HH; Chiu, SN; Hu, FC; Lin, MT; Lu, CW; Wang, JK; Wu, MH, 2013) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 7.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "Efficacy of losartan versus atenolol in the prevention of progressive dilation of the aorta, improved aortic distensibility, and prevention of adverse events (aortic dissection or rupture, cardiovascular surgery, or death) will be assessed in this study." | 6.76 | [Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome]. ( Centeno, J; Cortina, J; Evangelista, A; Forteza, A; García, D; García-Dorado, D; Gutiérrez, L; Rodríguez-Palomares, J; Sánchez, V; Sanz, P; Teixidó, G, 2011) |
| "The Pediatric Heart Network randomized trial of atenolol versus losartan in the Marfan syndrome showed no treatment differences in the rates of aortic-root growth or clinical outcomes." | 5.27 | Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome. ( Bradley, TJ; Campbell, MJ; Chen, S; Cohen, MS; Colan, SD; De Backer, J; Heydarian, H; Hoskoppal, A; Lacro, RV; Lai, WW; Levine, JC; Liou, A; Marcus, E; Nutting, A; Olson, AK; Parra, DA; Pearson, GD; Pierpont, ME; Printz, BF; Pyeritz, RE; Ravekes, W; Roman, MJ; Selamet Tierney, ES; Sharkey, AM; Sleeper, LA; Srivastava, S; Young, L, 2018) |
| "To evaluate the benefit of adding Losartan to baseline therapy in patients with Marfan syndrome (MFS)." | 5.20 | Marfan Sartan: a randomized, double-blind, placebo-controlled trial. ( Aegerter, P; Arnoult, F; Attias, D; Barthelet, M; Basquin, A; Boileau, C; Collignon, P; Delorme, G; Detaint, D; Dulac, Y; Dupuis-Girod, S; Edouard, T; Faivre, L; Habib, G; Jondeau, G; Milleron, O; Naudion, S; Odent, S; Pangaud, N; Plauchu, H; Ropers, J; Sassolas, F; Thomas-Chabaneix, J; Tubach, F; Wolf, JE, 2015) |
| "In this multicentre, open-label, randomized controlled trial with blinded assessments, we compared losartan treatment with no additional treatment in operated and unoperated adults with Marfan syndrome." | 5.17 | Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. ( de Waard, V; den Hartog, AW; Franken, R; Groenink, M; Marquering, HA; Mulder, BJ; Radonic, T; Scholte, AJ; Spijkerboer, AM; Timmermans, J; van den Berg, MP; Zwinderman, AH, 2013) |
| "To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS)." | 5.17 | Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. ( Chen, CA; Chiu, HH; Chiu, SN; Hu, FC; Lin, MT; Lu, CW; Wang, JK; Wu, MH, 2013) |
| "The Pediatric Heart Network is conducting a large international randomized trial to compare aortic root growth and other cardiovascular outcomes in 608 subjects with Marfan syndrome randomized to receive atenolol or losartan for 3 years." | 4.89 | Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome. ( Bradley, TJ; Campbell, MJ; Chen, S; Cohen, MS; Colan, SD; De Backer, J; Guey, LT; Heydarian, H; Lacro, RV; Lai, WW; Levine, JC; Lewin, MB; Marcus, E; Mart, CR; Pearson, GD; Pignatelli, RH; Printz, BF; Selamet Tierney, ES; Sharkey, AM; Shirali, GS; Sleeper, LA; Srivastava, S, 2013) |
| "The anti-atherosclerosis effects of Ang-(1-7) and losartan in early lesion formation were equivalent." | 3.81 | Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice. ( Dong, M; Guan, J; Meng, X; Niu, R; Sun, Y; Yang, J; Yang, X; Zhang, C; Zhang, Y, 2015) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 3.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "Statins are similar to losartan in attenuating aortic root dilation in a mouse model of Marfan syndrome." | 3.77 | Pravastatin reduces Marfan aortic dilation. ( Black, A; Byrne, J; Dietz, HC; Hill, AD; Huuskonen, V; Kay, E; Kearney, S; McAllister, H; McGuinness, J; McLoughlin, D; Redmond, JM; Terzo, E, 2011) |
| "Efficacy of losartan versus atenolol in the prevention of progressive dilation of the aorta, improved aortic distensibility, and prevention of adverse events (aortic dissection or rupture, cardiovascular surgery, or death) will be assessed in this study." | 2.76 | [Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome]. ( Centeno, J; Cortina, J; Evangelista, A; Forteza, A; García, D; García-Dorado, D; Gutiérrez, L; Rodríguez-Palomares, J; Sánchez, V; Sanz, P; Teixidó, G, 2011) |
| "Uremia was induced in apoE-/- mice by 5/6 nephrectomy (NX)." | 1.34 | Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice. ( Binder, CJ; Bro, S; Nielsen, LB; Olgaard, K; Witztum, JL, 2007) |
| "Losartan treatment reduced lesion area at the aortic sinus, although differences were only significant in female mice." | 1.33 | Differential effects of angiotensin II on atherogenesis at the aortic sinus and descending aorta of apolipoprotein-E-deficient mice. ( Catanzaro, DF; Catanzaro, SE; Chen, R; Dansky, HM; Hu, L; Zhou, Y, 2005) |
| "Development of cardiac hypertrophy in ACF seemed independent of angiotensin II." | 1.30 | Interaction between the renin-angiotensin system and insulin-like growth factor I in aorto-caval fistula-induced cardiac hypertrophy in rats. ( Friberg, P; Isgaard, J; Wåhlander, H; Wickman, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 5 (20.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Woudstra, OI | 1 |
| Ghanam, A | 1 |
| Vliegen, HW | 1 |
| van Dijk, APJ | 1 |
| van Melle, JP | 1 |
| Groenink, M | 3 |
| Meijboom, FJ | 1 |
| Post, MC | 1 |
| Mulder, BJM | 1 |
| Bouma, BJ | 1 |
| Bokma, JP | 1 |
| Flyer, JN | 1 |
| Sleeper, LA | 3 |
| Colan, SD | 3 |
| Singh, MN | 1 |
| Lacro, RV | 3 |
| Selamet Tierney, ES | 2 |
| Levine, JC | 2 |
| Roman, MJ | 1 |
| Bradley, TJ | 2 |
| Chen, S | 2 |
| Campbell, MJ | 2 |
| Cohen, MS | 2 |
| De Backer, J | 3 |
| Heydarian, H | 2 |
| Hoskoppal, A | 1 |
| Lai, WW | 2 |
| Liou, A | 1 |
| Marcus, E | 2 |
| Nutting, A | 1 |
| Olson, AK | 1 |
| Parra, DA | 1 |
| Pearson, GD | 2 |
| Pierpont, ME | 1 |
| Printz, BF | 2 |
| Pyeritz, RE | 1 |
| Ravekes, W | 1 |
| Sharkey, AM | 2 |
| Srivastava, S | 2 |
| Young, L | 1 |
| Kang, YN | 1 |
| Chi, SC | 1 |
| Wu, MH | 2 |
| Chiu, HH | 2 |
| Guey, LT | 1 |
| Lewin, MB | 1 |
| Mart, CR | 1 |
| Pignatelli, RH | 1 |
| Shirali, GS | 1 |
| Trindade, PT | 1 |
| den Hartog, AW | 1 |
| Franken, R | 3 |
| Radonic, T | 1 |
| de Waard, V | 2 |
| Timmermans, J | 2 |
| Scholte, AJ | 2 |
| van den Berg, MP | 2 |
| Spijkerboer, AM | 1 |
| Marquering, HA | 1 |
| Zwinderman, AH | 2 |
| Mulder, BJ | 3 |
| Milleron, O | 1 |
| Arnoult, F | 1 |
| Ropers, J | 1 |
| Aegerter, P | 1 |
| Detaint, D | 1 |
| Delorme, G | 1 |
| Attias, D | 1 |
| Tubach, F | 1 |
| Dupuis-Girod, S | 1 |
| Plauchu, H | 1 |
| Barthelet, M | 1 |
| Sassolas, F | 1 |
| Pangaud, N | 1 |
| Naudion, S | 1 |
| Thomas-Chabaneix, J | 1 |
| Dulac, Y | 1 |
| Edouard, T | 1 |
| Wolf, JE | 1 |
| Faivre, L | 1 |
| Odent, S | 1 |
| Basquin, A | 1 |
| Habib, G | 1 |
| Collignon, P | 1 |
| Boileau, C | 1 |
| Jondeau, G | 1 |
| Yang, J | 1 |
| Sun, Y | 1 |
| Dong, M | 1 |
| Yang, X | 1 |
| Meng, X | 1 |
| Niu, R | 1 |
| Guan, J | 1 |
| Zhang, Y | 1 |
| Zhang, C | 1 |
| El Morabit, A | 1 |
| Marquering, H | 1 |
| Planken, NR | 1 |
| Yamamoto, S | 1 |
| Zhong, J | 1 |
| Yancey, PG | 1 |
| Zuo, Y | 2 |
| Linton, MF | 2 |
| Fazio, S | 2 |
| Yang, H | 1 |
| Narita, I | 1 |
| Kon, V | 2 |
| Lüscher, TF | 1 |
| Gao, L | 1 |
| Chen, L | 1 |
| Fan, L | 1 |
| Gao, D | 1 |
| Liang, Z | 1 |
| Wang, R | 1 |
| Lu, W | 1 |
| Gonzalez, EA | 1 |
| Tavares, AM | 1 |
| Poletto, E | 1 |
| Giugliani, R | 1 |
| Matte, U | 1 |
| Baldo, G | 1 |
| Chan, EC | 1 |
| Jones, GT | 1 |
| Dusting, GJ | 1 |
| Datla, SR | 1 |
| Jiang, F | 1 |
| Forteza, A | 1 |
| Evangelista, A | 1 |
| Sánchez, V | 1 |
| Teixidó, G | 1 |
| García, D | 1 |
| Sanz, P | 1 |
| Gutiérrez, L | 1 |
| Centeno, J | 1 |
| Rodríguez-Palomares, J | 1 |
| Cortina, J | 1 |
| García-Dorado, D | 1 |
| McLoughlin, D | 1 |
| McGuinness, J | 1 |
| Byrne, J | 1 |
| Terzo, E | 1 |
| Huuskonen, V | 1 |
| McAllister, H | 1 |
| Black, A | 1 |
| Kearney, S | 1 |
| Kay, E | 1 |
| Hill, AD | 1 |
| Dietz, HC | 1 |
| Redmond, JM | 1 |
| Wang, JK | 1 |
| Lu, CW | 1 |
| Chiu, SN | 1 |
| Chen, CA | 1 |
| Lin, MT | 1 |
| Hu, FC | 1 |
| Keidar, S | 1 |
| Kaplan, M | 1 |
| Pavlotzky, E | 1 |
| Coleman, R | 1 |
| Hayek, T | 1 |
| Hamoud, S | 1 |
| Aviram, M | 1 |
| Zhou, Y | 1 |
| Chen, R | 1 |
| Catanzaro, SE | 1 |
| Hu, L | 1 |
| Dansky, HM | 1 |
| Catanzaro, DF | 1 |
| Bro, S | 1 |
| Binder, CJ | 1 |
| Witztum, JL | 1 |
| Olgaard, K | 1 |
| Nielsen, LB | 1 |
| Suganuma, E | 1 |
| Babaev, VR | 1 |
| Motojima, M | 1 |
| Ayabe, N | 1 |
| Fogo, AB | 1 |
| Ichikawa, I | 1 |
| Wåhlander, H | 1 |
| Wickman, A | 1 |
| Isgaard, J | 1 |
| Friberg, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome[NCT00763893] | Phase 3 | 303 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to A similar publication has been released, suggesting a beneficial effect of sartans, and only 15 patients remained to be seen for their visit at 36 months.) | ||
| Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR)[NCT02679261] | Phase 3 | 220 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome[NCT00651235] | Phase 2 | 44 participants (Anticipated) | Interventional | 2007-02-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for losartan and Aortic Diseases
| Article | Year |
|---|---|
The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Aortic Diseases; Cardiotonic Agents; | 2020 |
Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Analysis of Variance; Angiotensin II Type | 2013 |
The effect of losartan on progressive aortic dilatation in patients with Marfan's syndrome: a meta-analysis of prospective randomized clinical trials.
Topics: Aortic Diseases; Dilatation, Pathologic; Echocardiography; Female; Humans; Losartan; Magnetic Resona | 2016 |
7 trials available for losartan and Aortic Diseases
| Article | Year |
|---|---|
The aortic root in repaired tetralogy of Fallot: Serial measurements and impact of losartan treatment.
Topics: Adult; Aorta; Aortic Diseases; Dilatation, Pathologic; Female; Humans; Losartan; Male; Middle Aged; | 2021 |
Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome.
Topics: Adolescent; Aorta; Aortic Diseases; Atenolol; Cardiac Imaging Techniques; Child; Child, Preschool; D | 2018 |
Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Aorta, Thoracic; Aortic Diseases; Dilatation, Pathol | 2013 |
Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Aorti | 2015 |
Increased aortic tortuosity indicates a more severe aortic phenotype in adults with Marfan syndrome.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Diseases; Aortic Dissection; Dilatatio | 2015 |
[Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome].
Topics: Adolescent; Adult; Antihypertensive Agents; Aorta; Aortic Diseases; Atenolol; Child; Child, Preschoo | 2011 |
Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Aortic | 2013 |
15 other studies available for losartan and Aortic Diseases
| Article | Year |
|---|---|
Effect of Losartan or Atenolol on Children and Young Adults With Bicuspid Aortic Valve and Dilated Aorta.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; | 2021 |
Losartan treatment in adult patients with Marfan syndrome: can we finally COMPARE?
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Female; Humans; Losartan; Male; Marfan Syn | 2013 |
Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Abdominal; Aortic Diseases; | 2015 |
Marfan and Sartans: time to wake up!
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Female; Humans; Losartan; Male; Marfan Syn | 2015 |
Aortic disease: Losartan versus atenolol in the Marfan aorta-how to treat?
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Female; Humans; Losartan; Male; Marfan Syn | 2015 |
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atheroscle | 2015 |
Atherosclerosis, neoatherosclerosis, and vascular disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Aortic Valve Stenosis; Cardiovascular Dise | 2015 |
Losartan improves aortic dilatation and cardiovascular disease in mucopolysaccharidosis I.
Topics: Aortic Diseases; Cardiovascular Diseases; Dilatation; Humans; Losartan; Mucopolysaccharidosis I | 2017 |
Prevention of aortic elastic lamina defects by losartan in apolipoprotein(E)-deficient mouse.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Diseas | 2009 |
Pravastatin reduces Marfan aortic dilation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Dilatation, Pathologic; Di | 2011 |
Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
Differential effects of angiotensin II on atherogenesis at the aortic sinus and descending aorta of apolipoprotein-E-deficient mice.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta, Thoracic; Aortic Diseases; Apolipoproteins | 2005 |
Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodi | 2007 |
Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aortic Di | 2007 |
Interaction between the renin-angiotensin system and insulin-like growth factor I in aorto-caval fistula-induced cardiac hypertrophy in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, Abdominal; Aortic | 1999 |